Striving to Ensure Medicines Reach Those Who Need Them
Foundational medicines, such as antibiotics, are essential, life-saving drugs used to treat common and serious health conditions. They form the backbone of modern healthcare systems and are included in the World Health Organization’s Model List of Essential Medicines for their efficacy, safety, and cost-effectiveness. Making antibiotics available to the people who need them is the foundation to Centrient's purpose: improving lives through the innovative and sustainable manufacturing of medicines.
As one of the key European manufacturers of compounds like penicillin G, Centrient safeguards supply chain resilience through backward integration and multi-site production, helping to prevent shortages and support healthcare systems worldwide.
Centrient's commitments
Centrient holds a strong position in the critical medicines supply chain. We play a vital role in ensuring the reliable supply of products such as active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), helping to prevent infections, facilitate medical treatments and improve people’s overall quality of life. Today, 69% of our portfolio is included on the World Health Organization’s (WHO) Model List of Essential Medicines. As such, Centrient has the following target set in its ESG strategy:
- Increasing access to our foundational medicine portfolio to 2 billion patients by 2030
What we achieved in 2024
1.57 billion patient treatments facilitated in 2024
In addition to the patient treatments facilitated, Centrient also took steps to remain committed to improving patient access to foundational medicines, most notably:
- Investing EUR 5 million to expand our biosynthetic manufacturing site in Yushu, China, which produces many of the intermediates for our semi-synthetic penicillins (SSPs)
- Joining the Critical Medicines Alliance (CMA) to advocate for the strengthening of European supply chains for critical medicines and boost the resilience of European pharmaceutical manufacturing